Topline results from Remygen® trial in individuals with long-term Type 1 Diabetes
Uppsala University Hospital’s ReGenerate-1 trial evaluating Diamyd Medical’s Remygen[®] in individuals with long-term Type 1 Diabetes met the primary endpoint of safety. No clear support for a durable treatment effect on increasing endogenous insulin production measured as C-peptide or preventing hypoglycemia (sharply lowered blood glucose levels) by improving the protective counterregulatory hormonal response was observed. A potential trend for an immediate effect, e.g directly following ingestion of Remygen[®], on improving counterregulatory hormonal responses was observed in the higher